Method for thawing, culturing, selecting and transferring frozen embryos and non-invasive detection method for thawing frozen embryos

Resuscitation and non-invasive gene detection of frozen embryos through microdroplet culture system, combined with morphological evaluation priority assessment, solve the detection problems during embryo cryogenic resuscitation, improve the accuracy of embryo transfer success rate and transplant timing, and reduce multiple pregnancy risk.

CN114752552BActive Publication Date: 2024-11-12XUKANG MEDICAL SCI & TECH (SUZHOU) CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202210495023.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-05-07
Publication Date
2024-11-12
Estimated Expiration
2042-05-07

AI Technical Summary

Technical Problem

The existing lack of effective non-invasive chromosome detection methods during the freezing and resuscitation of embryos leads to a low success rate of embryo transfer, high pregnancy rate for multiple fetuses, and the culture time of embryos after freezing and resuscitation is too long, which misses the best transplantation opportunity, affecting the implantation rate. .

Method used

The frozen embryos were resuscitated and gene/chromosome detection were performed using a microdroplet culture system. CfDNA was collected in the culture medium for non-invasive PGT-A detection, embryo priority was evaluated in combination with morphological evaluation, and transplanted at the optimal time.

Benefits of technology

It improves the success rate of frozen embryo transfer, reduces the risk of embryo damage, ensures the optimal time for embryo transfer, and reduces the rate of multiple pregnancy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114752552B_ABST
    Figure CN114752552B_ABST
Patent Text Reader

Abstract

The present invention provides a non-invasive detection method for thawing frozen embryos, and a method for thawing and culturing frozen embryos for obtaining test samples. The present invention also provides an embryo optimization method for evaluating the priority level of embryo transplantation using the test results, which is used in single blastocyst transplantation, and thus the present invention also provides a corresponding single blastocyst transplantation method and system.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of assisted reproductive technology. Specifically, the present invention relates to a series of methods for embryo freezing / thawing in in vitro fertilization-embryo transfer technology, including a non-invasive detection method for thawing frozen embryos, and a method for thawing and culturing frozen embryos for obtaining test samples, as well as an embryo selection method for evaluating the priority level of embryo transplantation using the test results, and a corresponding single blastocyst transplantation method and system. Background Art

[0002] In vitro fertilization-embryo transfer (IVF-ET) is one of the ultimate solutions for couples who have difficulty conceiving to have offspring. To date, more than 8 million babies have been born worldwide with the help of IVF-ET technology. In this process, because multiple embryo transfers are generally attempted during embryo transfer, the multiple pregnancy rate remains high, currently reaching 20%. Multiple pregnancies can increase adverse pregnancy outcomes and endanger the health of mothers and babies. Selective single blastocyst transfer (eSET) is the most effective method to reduce the multiple pregnancy rate and is increasingly used internationally. Under this trend, it is crucial to improve the success rate of single embryo transfer, but there is still a lack of scientific methods for evaluating the potential for embryo development.

[0003] Chromosomal aneuploidy can lead to stagnation of embryo development or failure of embryo implantation, and is an important factor leading to low IVF pregnancy rates and high miscarriage rates. Among aborted fetuses, aneuploidy accounts for more than 50%. At present, the most commonly used embryo selection method is traditional morphological evaluation, but it cannot identify the chromosome status of the embryo alone. Therefore, preimplantation genetic testing for aneuploidy (PGT-A) can be implemented for people at high risk of chromosomal aneuploidy to analyze the copy number of embryo chromosomes before implantation. However, if the pregnant woman fails to choose PGT-A in the first cycle, if implantation failure or miscarriage occurs, she can only continue to select the remaining frozen embryos through morphological rating, and the chromosome status cannot be confirmed.

[0004] If this group of people plans to choose PGT-A testing after a failed implantation or miscarriage, they will need to undergo a series of operations such as invasive embryo biopsy and secondary freezing after embryo thawing, which may damage the embryo. Therefore, for this group of people, if non-invasive chromosome screening can be used to detect the chromosome ploidy of the embryo, the embryo biopsy operation can be avoided after thawing, greatly reducing the possibility of embryo damage.

[0005] During the culture process, embryos release cfDNA into the culture medium. In recent years, non-invasive PGT-A testing using cfDNA has become a research hotspot in the field of assisted reproduction. In particular, relevant studies on the culture medium of frozen and thawed embryos have shown that frozen embryo culture medium has been proven to be more suitable for non-invasive preimplantation genetic aneuploidy testing (niPGT) compared with fresh embryo culture medium. Studies usually collect culture medium or a mixture of blastocyst cavity fluid and culture medium for 14-24 hours after frozen embryo thaw. The success rate of sample amplification is 92.3-100%. The results of the whole embryo are used as the gold standard to compare the consistency of the culture medium results with the whole embryo results, and the accuracy can reach 87-100%. The results of Kuznyetsov et al. showed that the consistency of NICS results with whole embryo results even exceeded the consistency of TE results with whole embryo results (96.4% vs 87.5%). However, usually in the freezing-thawing cycle, the frozen embryo thawing and culture time in the above studies is relatively long (14-24h). For the frozen blastocysts that have reached the freezing standards, the in vitro culture time is too long, and the best time for embryo implantation is missed, which is not suitable for application in actual clinical work.

[0006] At present, in clinical practice, embryos are routinely graded for morphology on the 5th to 7th day of embryonic development (blastocyst stage), and blastocysts with a grade of 3BC or above are selected for freezing, and laser shrinkage is performed before freezing. Embryo freezing mostly uses vitrification technology, and the carriers used more frequently in clinical practice are cryoleaf, cryotop, and cryoloop. Both freezing and thawing fluids are purchased as commercial products, such as Kato Company of Japan. The process of blastocyst freezing is: balance and wash the blastocyst, then put it into a tube and load it, and freeze it in liquid nitrogen. During recovery, the blastocyst is balanced, washed and cultured. The expansion of the blastocyst cavity after 2 hours of recovery indicates that the recovery is successful. Most centers directly transplant blastocysts after 2-3 hours of culture. Some centers will culture overnight (18-20h) and then transplant the embryos into the patient. Some centers will biopsy the embryos, freeze the embryos again, and after the biopsy results come out, the euploid embryos will be revived for transplantation.

[0007] The present invention provides an improved embryo recovery and culture method for detecting, culturing and evaluating frozen blastocysts. Brief description of the invention

[0008] The inventors of the present invention have explored a series of operating conditions and / or detection and evaluation methods for embryo freezing / thawing through long-term experience accumulation and research verification, so as to maximize the success rate of frozen embryo transplantation and ensure that pregnant women who receive frozen embryo transplantation obtain the best outcome.

[0009] In one aspect, the present invention provides a method for thawing frozen embryos, the method comprising: (1) obtaining frozen embryos to be thawed from a pregnant woman; (2) thawing the frozen embryos and transferring them into a microdroplet culture system for culture for a culture time of T1.

[0010] In a more specific embodiment, the T1 is 4-10 hours, preferably 6-8 hours, more preferably 6 hours.

[0011] In another preferred embodiment, the volume of the microdroplet culture system is 10-20 μL, preferably 15 μL, and more preferably 10 μL.

[0012] In a second aspect, the present invention provides a method for preparing a test sample after thawing of a frozen embryo, wherein the test sample is used for gene / chromosome testing of the embryo, such as euploidy testing, and the method is characterized in that the embryo is revived and cultured using the thawing method of the first aspect of the present invention, and after the culture is completed, the culture fluid in the culture system is obtained as a test sample.

[0013] In a specific embodiment, the culture time is 4-10 hours, preferably 6-8 hours, more preferably 6 hours. In another preferred embodiment, the volume of the microdroplet culture system is 10-20 μL, preferably 15 μL, more preferably 10 μL.

[0014] In a third aspect, the present invention provides a method for detecting genes / chromosomes after thawing frozen embryos, so as to detect whether the embryos have abnormal conditions in genes / chromosomes, for example, euploidy / aneuploidy of chromosomes. The method is characterized in that the embryos are revived and cultured using the thawing method of the first aspect of the present invention, and the test sample is obtained using the test sample preparation method of the second aspect of the present invention.

[0015] In a preferred embodiment, the embryo gene / chromosome detection method is non-invasive chromosome screening (NICS).

[0016] In a specific embodiment, the culture time is 4-10 hours, preferably 6-8 hours, more preferably 6 hours. In another preferred embodiment, the volume of the microdroplet culture system is 10-20 μL, preferably 15 μL, more preferably 10 μL.

[0017] In some embodiments, the detection result of the gene / chromosome detection method is that the free DNA from the embryo in the sample is detected to have euploidy, so the chromosomes of the embryo are euploid. In other embodiments, the result of the detection is that the free DNA from the embryo in the sample is detected to have aneuploidy, so the chromosomes of the embryo are aneuploid, for example, 21-trisomy, 18-trisomy, etc. In other embodiments, the result of the detection is that the free DNA from the embryo in the sample is detected to have aneuploidy, so the chromosomes of the embryo are aneuploid, for example, 21-trisomy, 18-trisomy, etc. In other embodiments, the result of the detection is "NA" (Not Available), that is, amplification failure occurs, amplification failure leads to insufficient sequencing data for analysis, and the sequencing data of the amplified product does not meet the analysis standard, so no ploidy detection result for the embryo is obtained.

[0018] In a fourth aspect, the present invention provides a method for frozen embryo transfer, which can obtain the best clinical outcome, i.e., continued pregnancy and live birth, with the highest probability among candidate embryos. The method comprises the following steps:

[0019] a) Obtaining frozen embryos ready for thawing from prospective pregnant women;

[0020] b) thawing the frozen embryos and transferring them into a microdroplet culture system for culture for a period of time of T1;

[0021] c) collecting the culture medium, amplifying the cfDNA therein, and then conducting embryonic chromosome genetic testing;

[0022] d) Prioritization of embryos based on the results of chromosome genetic testing and morphological assessment prior to embryo freezing;

[0023] e) Transferring embryos with higher priority to prospective pregnant women.

[0024] In a specific embodiment, the culture time is 4-10 hours, preferably 6-8 hours, more preferably 6 hours. In another preferred embodiment, the volume of the microdroplet culture system is 10-20 μL.

[0025] In some embodiments, the result of the embryo chromosome genetic test is one of the following three: euploid, NA, and aneuploid.

[0026] In some embodiments, the result of the embryo morphology assessment is one of the following three: excellent, fair, and poor.

[0027] In a preferred embodiment, the criteria for embryo priority assessment are: comprehensive chromosome genetic test results and morphological assessment results, and assessment is made according to euploid + excellent > NA + excellent > euploid + medium > NA + medium.

[0028] In a preferred embodiment, the required number of embryos are transferred to prospective pregnant women according to their priority levels, wherein for embryos that are aneuploid by genetic testing and / or poor by morphological assessment, the decision on whether to transfer them needs to be made by the clinician and the patient together after the patient is fully informed of the risks.

[0029] Thus accordingly, in another aspect, the present invention provides a method for assessing the transplantation priority of an embryo, the method being characterized in that, the embryo chromosome genetics test result obtained by the detection method of the third aspect of the present invention is combined with the result of the morphological evaluation performed before the embryo is frozen to assess the embryo priority. In some embodiments, the result of the embryo chromosome genetics test is one of the following three types: euploid, NA, and aneuploid. In some embodiments, the result of the embryo morphological evaluation is one of the following three types: excellent, medium, and poor. In a preferred embodiment, the standard for embryo priority assessment is: comprehensive chromosome genetics test results and morphological evaluation results, and assessment is made according to euploid + excellent > NA + excellent > euploid + medium > NA + medium.

[0030] In another aspect, the present invention provides a method for preferably freezing embryos, the method being characterized in that the transplantation priority of candidate embryos is evaluated using the above-mentioned transplantation priority evaluation method. In some embodiments, the evaluation result of the embryo is euploid + excellent, and thus is the most preferred embryo for transplantation. In some embodiments, the evaluation result of the embryo is NA + excellent, and thus is a suboptimal embryo for transplantation. In some embodiments, the evaluation result of the embryo is euploid + medium, and thus is an embryo that is again excellent for transplantation. In some embodiments, the evaluation result of the embryo is NA + medium, and thus is an embryo that can still be used for transplantation. In some embodiments, the evaluation result of the embryo is that genetic detection is aneuploidy and / or morphological assessment is poor, and when the patient is fully informed of the risks, the clinician and the patient jointly decide whether to transplant.

[0031] In another aspect, the present invention provides a system for frozen embryo transfer, comprising the following modules:

[0032] 1) Embryo recovery and culture module: the module is used to recover and culture frozen embryos obtained from pregnant women;

[0033] 2) Embryo detection module: This module is used to collect the embryo culture medium in module 1) and perform embryo chromosomal genetic testing after amplifying the cfDNA therein. This module is also used to trace, obtain and / or receive the results of morphological evaluation before embryo freezing;

[0034] 3) Result analysis module: Based on the embryo chromosome genetic test results and morphological evaluation results output by module 2), the priority level of the corresponding embryo for transplantation is analyzed.

[0035] In some preferred embodiments, the embryo recovery culture module of the system adopts a droplet culture system with a culture volume of 10-20 μL, preferably 10 μL.

[0036] In some preferred embodiments, the embryo recovery culture module of the system adopts a culture time of 4-10 hours, preferably 6-8 hours, and more preferably 6 hours.

[0037] In some preferred embodiments, the chromosome genetic test output by the embryo detection module of the system is divided into three results: euploid, NA and aneuploid; the morphological evaluation is divided into three results: excellent, medium and poor. In some further embodiments, the result analysis module evaluates the priority of embryo transplantation from high to low according to the above results: euploid + excellent > NA + excellent > euploid + medium > NA + medium, and the embryos detected as aneuploid by genetics and / or poor by morphological evaluation are decided by the clinician and the patient together if the patient is fully informed of the risks. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 Shown is a full flow chart of the validation study of the method of the present invention.

[0039] Figure 2 The figure shows the embryo transplantation priority order determined by the embryo transplantation priority assessed by the method of the present invention. DETAILED DESCRIPTION OF THE INVENTION

[0040] In Vitro Fertilization-Embryo Transfer (IVF-ET), also known as the "test tube baby" technology by the public, is a scientific assisted reproductive technology (ART) that can quickly help pregnant women achieve pregnancy. The process is to remove gametes (sperm and eggs) from the human body, fertilize them in vitro to form embryos, and then select high-quality embryos to be transferred into the uterine cavity for implantation and development into fetuses. As can be seen from the name of the technology, the technology is divided into two stages: human gametes (sperm and eggs) are fertilized in vitro to form embryos and develop into blastocysts; the blastocysts are transferred into the uterine cavity of the pregnant woman so that the blastocysts complete implantation on the endometrium. After that, the process of embryo development is no different from the chance of natural conception.

[0041] IVF (In Vitro Fertilization) is the most commonly used method in the first stage, so its name is often used to refer to the first stage. The operation method of IVF is to directly add sperm to the egg after screening, and the two gametes can directly complete fertilization and combine to form an embryo. IVF is used when the male's sperm is normal or basically normal.

[0042] ICSI (intracytoplasmic sperm injection) is an alternative to IVF. When the male's sperm count is too low and / or too weak to enter the egg on its own, a single sperm is injected into the egg using microinsemination technology, thereby fertilizing the egg to form an embryo. Unless otherwise specified, the methods in this article are applicable to embryos formed by IVF, ICSI or other in vitro fertilization methods.

[0043] Unless otherwise specified, "pregnant", "subject" and "patient" are used interchangeably herein, meaning women who intend to receive IVF-ET to conceive (obtain pregnancy). Although in many cases, such women have failed to conceive naturally after long-term and multiple attempts, this does not mean that such women suffer from diseases, because the reasons for failure to conceive naturally are diverse and complex (disease is only part of it), and it does not mean that IVF-ET can treat any disease that the woman may suffer from, and the pregnant woman is only habitually referred to as a "patient" when receiving services in clinical institutions. The conversion of non-pregnant / pregnant state is a conversion of physiological processes (although it is complex and sophisticated), and the only purpose of IVF-ET is to quickly and reliably establish a pregnancy state. In most cases, when the pregnant woman receives IVF-ET, she and / or her spouse do not need to be actually diagnosed with any disease. Even if the pregnant woman suffers from a disease that makes it difficult / impossible to conceive naturally, IVF-ET often cannot definitely treat the disease, but only provides an alternative to natural conception.

[0044] Blastocyst is a stage in the embryonic development process, in which the embryo contains the blastocyst cavity, the dense inner cell mass and the trophoblast cells. During natural conception and during embryo transfer, when the embryo develops to the blastocyst stage, it can implant on the endometrium. Therefore, unless otherwise specified, "blastocyst" and "embryo" are used interchangeably in this article.

[0045] Unless otherwise specified, "D" + a number herein represents the day of development after embryo formation (e.g., in vitro formation). For example, but not limiting, D5 represents the 5th day after embryo formation, and D6 represents the 6th day after embryo formation.

[0046] Blastocyst freezing, also known as blastocyst vitrification, refers to a method of storing embryos that have developed to the blastocyst stage in a liquid nitrogen environment at minus 196°C for long-term preservation. When multiple high-quality embryos are obtained through in vitro fertilization and are not all used in a single transplant, or when fresh embryos cannot be transplanted due to maternal reasons, one or more blastocysts can be frozen, and when needed or suitable for embryo transplantation, the blastocysts are revived and used for transplantation. A blastocyst freezing / revivification method suitable for the present invention is, for example, using a Japanese Kato freezing and thawing kit (Kitazato Biophama Co. Ltd. Shizuoka. Japan) according to the operating instructions of the manual. The freezing reagent includes an equilibrium solution (ES) and a freezing solution (VS); the thawing reagent contains a thawing solution (TS), a diluent (DS), a washing solution 1 (WS1) and a washing solution 2 (WS2); and the freezing carrier is Cryotop (produced by Kato, Japan). Before the blastocyst is frozen, a laser-assisted hatching system is used to artificially shrink the cystic cavity at the zona pellucida on the side away from the inner cell mass, release the blastocyst fluid, and vitrify it after complete shrinkage. The freezing process is at 37°C, in ES solution for 2 minutes, in VS for 45-60 seconds, and then the embryo is placed on the top of the freezing carrier Cryotop and immediately plunged into liquid nitrogen. During the blastocyst recovery process, the freezing carrier loaded with the blastocyst is taken out of the liquid nitrogen, quickly placed in the TS that has been balanced to 37°C for 1 minute, and then transferred to DS, WS1 and WS2 balanced at room temperature in turn, each step for 3 minutes. After recovery, G2.5PLUS (Vitrolife) is used for microdroplet culture (for example, 15-20 microliters) before transplantation. In a preferred embodiment of the present invention, the blastocyst is frozen on day D5 or D6. In a more preferred embodiment of the present invention, the blastocyst is frozen on day D5.

[0047] The frozen embryo recovery culture scheme preferably adopted by the present invention is as follows: the blastocysts recovered by micro-drop culture of 15-20 μL culture fluid system are cultured for 6 hours, and the blastocyst culture fluid (SCM, spent culture medium) is collected for embryo chromosome genetic detection. Kuznyetsov et al. used a 25 μL system to recover frozen embryos, cultured for 24 hours, collected the blastocyst cavity fluid and the culture fluid mixture, and the amplification success rate reached 100%, and the consistency of the NICS results with the whole embryo results reached 96.4%. Huang et al. used 15 μL culture fluid to recover frozen embryos, cultured for 24 hours, collected the culture fluid, and the amplification efficiency was 92.3%, and the consistency with the whole embryo results was 93.8%. In the literature published by Jiao et al., 12 μL culture fluid was used to recover frozen embryos for 15 hours, and the mixture of blastocyst cavity fluid and culture fluid was collected. The amplification efficiency can reach 100%, and the consistency with the whole embryo results is 90.48%. Based on the above prior art, those skilled in the art are generally aware that, in clinical practice, the time for thawing and culturing frozen embryos is generally 2-3 hours. Too long a culturing time may cause embryos that have developed to the blastocyst stage to miss the optimal implantation time, affecting the implantation rate. In our study, we thawed and cultured frozen embryos for 6 hours, which is a routine thawing operation for frozen embryos in embryo laboratories of many reproductive centers. It can fully activate the developmental potential of thawing embryos, which is conducive to embryo implantation, and also meets the sample starting amount requirements for NICS testing.

[0048] In terms of development, not all embryos are created equally. High-quality embryos differ from low-quality embryos in many ways. Although there is still controversy, most scholars in this field believe that embryos with more perfect genetic material, more vigorous and rapid proliferation will be more conducive to implantation and subsequent development into complete individuals.

[0049] The term "morphological assessment" refers to a means of inferring the vitality and developmental potential of an embryo based on the morphology of the embryo, based on the fact that an embryo in a proliferation state with normal genetic material, adequate nutrient supply and vigorous metabolism will be reflected in its morphology. It is one of the most important means of embryo assessment before the emergence of PGT. There are a variety of morphological assessment standards proposed in the prior art. In a preferred embodiment of the present invention, a scoring system based on blastocyst expansion, inner cell mass and trophectoderm development is used, which is developed by Gardner and Schoolcraft. The evaluation criteria of this scoring system are: according to the size of the blastocyst cavity, it is divided into: Grade 1 (early blastocyst), the blastocyst cavity is less than 1 / 2 of the embryo volume; Grade 2 (blastocyst), the blastocyst cavity is larger than 1 / 2 of the embryo volume; Grade 3 (complete blastocyst), the blastocyst cavity almost fills the entire embryo; Grade 4 (expanded blastocyst), the blastocyst volume is enlarged, the blastocyst cavity is expanded, and the zona pellucida becomes thinner; Grade 5 (hatching blastocyst), the zona pellucida appears to be broken, and some trophoblast cells begin to hatch out of the zona pellucida; Grade 6 (hatched blastocyst), the blastocyst is completely hatched from the zona pellucida and separated from the zona pellucida. Only blastocysts with ≥3 levels will be considered for transplantation. The inner cell mass is scored according to 3 levels: Grade A, with a large number of cells, tightly clustered, and obvious protrusions; Grade B, with a small number of cells, sparse or clustered; Grade C, with very few cells and it is difficult to distinguish a clear inner cell mass structure. The trophoblast is scored in three grades: grade A, with a large number of cells forming a continuous epithelial-like structure; grade B, with a small number of cells, discontinuous epithelial-like structures, and looser; grade C, with very few cells. In a preferred embodiment of the present invention, blastocysts of AA, AB, or BA are evaluated as having excellent morphology; BB / AC are evaluated as having medium morphology; and CA / BC / CB are evaluated as having poor morphology.

[0050] The term "PGT" refers to Preimplantation Genetic Testing. In this article, "PGT" and "PGT-A" (Preimplantation Genetic Testing for Aneuploidy) are used interchangeably. The earliest PGT technology was invasive, and genetic testing was performed by biopsy of the embryo and obtaining blastomere cells or trophoblast cells. With the discovery of cell-free DNA released by embryonic cells into the culture system, non-invasive PGT (Non-invasive preimplantation genetic testing, niPGT) methods that collect this DNA for PGT testing have also begun to be increasingly adopted. In this article, the term "niPGT" and the term "NICS" (Non-invasive chromosome screening) are used interchangeably.

[0051] The term "non-invasive chromosome screening (NICS)" refers to a non-invasive PGT technology that uses embryonic free DNA through whole genome amplification (WGA) and next-generation sequencing (NGS) to reflect the chromosome status of the entire embryo. The content of free cell-free DNA in the culture medium is small or even extremely small, and its existence has not been discovered before (even if it is discovered, there is no effective detection method). However, the high throughput, high sensitivity and high automation of whole genome amplification and next-generation sequencing technology have changed this situation. The use of WGA and NGS technology effectively amplifies the free DNA in the embryo and effectively sequences it, which essentially forms a "low-coverage whole genome sequencing". Using the powerful computing power of modern computers and appropriate algorithms, limited sequencing data can also be fully aligned to the reference genome, so as to obtain analysis results when there is enough sample volume for analysis. There are currently two major sequencing platforms used for PGT or niPGT, which are Illumina's MiSeq and Thermo-Fisher Scientific's PersonalGenome Machine (PGM). There are differences between the two in data output and analysis after sequencing analysis. In the case of CNV analysis, in addition to NGS, detection methods such as microarray, SNP microarray, Realtime PCR, and CGH microarray can also be used for the purpose of NICS.After obtaining the sample according to the method of the present invention, a technician in this field can easily implement the genetic detection of the present invention according to the existing schemes in the prior art, such as Xu J, et al. (2016) Noninvasive chromosome screening of human embryos by genome sequencing of embryo culture medium for in vitro fertilization. Proceedings of the National Academy of Sciences of the United States of America 113 (42): 11907-11912 and Huang J, et al. (2021) Chromosome Screening of Human Preimplantation Embryos by Using Spent Culture Medium: Sample Collection and Chromosomal Ploidy Analysis. Journal of visualized experiments: JoVE (175) and other documents, or as described in the Chinese invention patent publication number CN 109536581 A previously applied for by the applicant, the above documents are incorporated herein by reference in their entirety.

[0052] Copy number variation (CNV) refers to a submicroscopic structural variation, which is a complex chromosomal structural variation derived from deletions and / or duplications in the genome and their combination compared to the reference sequence. If the CNV is abnormal, it means that the chromosome is not euploid.

[0053] Unless otherwise specified, the term "NA" means in this article that no meaningful results are obtained after the obtained embryo detection sample is tested (for example, amplification, library construction and sequencing). The generation of such results may be due to the denser embryonic cells, resulting in less DNA being released into the culture fluid, that is, such samples have a higher probability of coming from embryos with better morphology. Therefore, in the absence of euploid embryos, after fully explaining the risks to the pregnant woman and the pregnant woman's fully informed consent, embryos with excellent morphological assessment but NA genetic test results are also preferred choices. In some embodiments of the present invention, the morphological assessment is excellent but the genetic test results are NA. The resuscitation frozen blastocysts are transplanted to the pregnant woman.

[0054] The following examples provide exemplary embodiments of the present invention. Although various embodiments have been described for the purpose of the present invention, these embodiments should not be considered to limit the teachings of the present invention to this. Various changes and modifications based on the embodiments to obtain the same or similar results are also within the scope of protection of the present invention. Example

[0055] Example 1. Experimental Design and Subjects

[0056] The present invention conducted a retrospective cohort study: 212 blastocyst culture fluids of pregnant women who underwent single blastocyst transfer according to morphologically optimized frozen embryos were collected from January 2019 to July 2019 in a certain center. Inclusion criteria: pregnant women have frozen embryos and agree to single blastocyst transfer according to morphological optimization. Exclusion criteria: pregnant women have hydrosalpinx and have not undergone proximal tubal ligation; pregnant women have endocrine factors, infectious factors, immune dysfunction and other diseases; pregnant women have endometrial polyps and have not been treated before thawing and transplantation.

[0057] A total of 212 pregnant women were transplanted with single blastocysts that were frozen according to morphological optimization. The morphological scoring standard was the scoring system developed by Gardner and Schoolcraft based on blastocyst expansion, inner cell mass and trophectoderm development. Single blastocysts were transplanted 6 hours after frozen embryos were thawed, and microdroplet culture medium was collected and cryopreserved for NICS testing. The pregnant women were followed up until live birth, and the relationship between NICS results and clinical outcomes was analyzed.

[0058] The observation indicators are as follows:

[0059] (1) Diagnosis and follow-up of pregnancy

[0060] The follow-up endpoint was live birth. Clinical pregnancy was defined as the presence of a gestational sac and fetal heartbeat in the uterine cavity confirmed by ultrasound 28-30 days after transplantation, ongoing pregnancy was defined as pregnancy ≥12 weeks and positive fetal heart activity, early miscarriage was defined as the loss of clinical pregnancy (at least one gestational sac) after ultrasound monitoring before 12 weeks of pregnancy, and live birth was defined as the delivery of a live infant with a gestational age of more than 28 weeks.

[0061] (2) Data calculation formula

[0062] Clinical pregnancy rate = number of clinical pregnancy cycles / number of thawing and transplantation cycles, ongoing pregnancy rate = number of ongoing pregnancy cycles / number of thawing and transplantation cycles, abortion rate = number of abortion cycles / number of clinical pregnancy cycles, live birth rate = number of live birth cycles / number of thawing and transplantation cycles.

[0063] Example 2. Materials and methods

[0064] I. NICS sample collection

[0065] Embryo cryopreservation and thawing

[0066] The blastocysts were frozen and revived using the Kitazato Biophama Co. Ltd. Shizuoka Japan freezing and thawing kit. The freezing reagents included equilibration solution (ES) and freezing solution (VS); the thawing reagents included thawing solution (TS), diluent (DS), washing solution 1 (WS1) and washing solution 2 (WS2); and the cryocarrier was Cryotop (produced by Kato Co., Ltd., Japan). Before freezing the blastocysts, the zona pellucida on the side away from the inner cell mass was artificially shrunk by a laser-assisted hatching system to release the blastocyst fluid, and the blastocyst fluid was vitrified after complete shrinkage. The freezing process was at 37°C for 2 minutes in ES solution and 45-60 seconds in VS, and then the embryos were placed on the top of the cryocarrier Cryotop and immediately plunged into liquid nitrogen. During the blastocyst resuscitation process, the cryocarrier containing the blastocysts was taken out of the liquid nitrogen, quickly placed in TS that had been equilibrated to 37°C for 1 minute, and then transferred to DS, WS1 and WS2 that were equilibrated at room temperature, with each step lasting 3 minutes. After thawing, G2.5PLUS (Vitrolife) was used for micro-droplet culture (15-20 μl) until transplantation.

[0067] Culture medium collection

[0068] Before embryo transfer, transfer the revived blastocyst cultured in microdroplets to the transfer dish. Collect the microdroplet culture medium and collect the blank culture medium as a control. To ensure the sample detection rate, the microdroplet culture time is 6 hours. The microdroplet culture medium is transferred to a nuclease-free PCR tube with a pipette and stored at -20°C.

[0069] II. Sample Testing

[0070] Amplification, library construction and sequencing

[0071] Follow the instructions to use ChromInst TM (YikonGenomics) library kit was used for WGA and NGS library preparation. In short, DNA was first annealed with a random primer library, pre-amplified, and then exponentially amplified to 2 μg. The amplified product was prepared using a library construction kit, and the NGS library was quality controlled using Qubit3.0 and 1.5% agarose gel electrophoresis. Sequencing was performed using the Illumina platform, and approximately 2 million sequencing reads were obtained for each library.

[0072] CNV analysis

[0073] The data were analyzed and visualized using R, Python, etc. High-quality reads were counted along the entire genome with a bin size of 1Mb, and the reads were normalized by GC and reference datasets. The binary segmentation algorithm (CBS) was used to detect CNV fragments. The 30% mosaicism rate was set as the threshold for distinguishing aneuploidy from euploidy. When the mosaicism was lower than 30%, the embryo was classified as "euploid", and when the mosaicism was higher than 70%, the embryo was classified as "aneuploid". Failed amplification, insufficient sequencing data analysis due to failed amplification, and sequencing data of amplified products that did not meet the analysis criteria were classified as the "NA" group. All embryos were divided into euploid, aneuploid, and NA groups based on the above test results.

[0074] III. Data Analysis

[0075] IBM SPSS19 was used for data analysis. In the baseline characteristics, continuous variables were expressed as mean ± standard deviation (x-±s) if they were normally distributed, and one-way analysis of variance was used for the test; if they were not normally distributed, they were expressed as median and interquartile range, and the Kruskal-Wallis test was used. Baseline characteristics and count variables in stratified analysis were expressed as frequency and percentage, and analyzed using chi-square test or Fisher's exact test. Covariates with p < 0.1 and an impact on clinical outcomes were included in multivariate logistic regression analysis to compare the clinical outcomes of the euploid group, aneuploid group, and NA group.

[0076] Example 3. Comparison of embryo recovery and culture time

[0077] Experimental steps:

[0078] A total of 58 frozen discarded blastocysts donated by a certain center were collected and resuscitated according to the instructions of the thawing kit (Kitazato Biophama Co. Ltd. Shizuoka Japan). After resuscitation, they were cultured in microdroplets (20 μl) using G2.5PLUS (Vitrolife) and placed in a three-gas incubator. After 2 hours of culture, the blastocyst cavity expanded and was considered alive and suitable for transplantation.

[0079] The blastocysts were divided into 4 groups, and the culture time of each group was 2, 4, 8 and 10 hours respectively. The number of blastocysts allocated was as shown in Table 1. The expansion of the blastocyst cavity was observed 2 hours after recovery to determine whether the blastocyst was successfully recovered. Group 1 (2 hours) can directly collect the culture fluid into 5 μl sample preservation fluid, and the remaining embryos collect the culture fluid according to the grouping time. According to the lysis, amplification library construction and sequencing steps described in the present invention, the detection was carried out, and the amplification success rate was analyzed according to the library construction and sequencing results.

[0080] The 6-hour group used retrospective data from 32 embryos that were operated on in a routine clinical setting. After thawing, the frozen blastocysts were cultured for 6 hours before transplantation. The embryo culture medium was collected for testing at the same time. The collection and testing process of the culture medium was the same as above.

[0081] Experimental results:

[0082] After 1.2 hours, the expansion of the blastocyst cavity was observed, and 84 embryos out of a total of 90 blastocysts were successfully revived, as shown in Table 1.

[0083] Table 1. Blastocyst grouping and recovery

[0084] Group 1 (2 hours) Group 2 (4 hours) Group 3 (6 hours) Group 4 (8h) Group 5 (10h) Number of embryos received 10 15 32 20 13 Number of successfully recovered blastocysts 9 14 30 19 12

[0085] 2. Under the 6-hour culture time and 20μl culture system, the amplification success rate is 90%. The amplification success rates of 6h, 8h and 10h are not much different, as shown in Table 2. (Clinically, most centers cannot culture for 8h / 10h because the time is too long)

[0086] Table 2. Comparison of different culture time and amplification success rate results

[0087]

[0088] The comparative experimental results can guide the method of the present invention to adopt 6 hours as the optimal time for post-resuscitation culture and sampling of culture fluid, and 4-10 hours or 6-8 hours are also ideal choices.

[0089] Example 4. Comparison of embryo recovery culture system volumes

[0090] Experimental steps:

[0091] Thirty frozen discarded blastocysts donated by a center were collected and revived according to the instructions of the thawing kit (Kitazato Biophama Co. Ltd. Shizuoka Japan). After resuscitation, G2.5PLUS (Vitrolife) was used for microdroplet culture. The blastocysts were divided into 2 groups, and the culture medium system was 10μl and 15μl respectively. Then they were placed in a three-gas incubator for culture. After 2 hours of culture, the blastocyst cavity expanded and was considered alive and suitable for transplantation. Then the culture was continued for 4 hours.

[0092] The culture medium of all embryos was collected into 5 μl of sample preservation solution. The detection was performed according to the lysis, amplification, library construction and sequencing steps of the present invention, and the amplification success rate was analyzed according to the library construction situation and sequencing results.

[0093] The data for the 20 μl group were also based on the retrospective data from 32 embryos as described in Example 3.

[0094] Experimental results:

[0095] 1. After 2 hours, the expansion of the blastocyst cavity was observed, and 64 embryos out of a total of 67 embryos were successfully revived. See Table 3.

[0096] Table 3. Blastocyst grouping and recovery

[0097] Group 1 (10 μl) Group 2 (15 μl) Group 3 (20 μl) Number of embryos received 20 15 32 Number of successfully recovered blastocysts 19 15 30

[0098] 2. In a culture system with a culture time of 6 hours and a volume of 20 μl, the amplification success rate was 90%, while a smaller culture volume achieved a higher amplification success rate. (As shown in Table 4)

[0099] Table 4. Comparison of 10-20μl culture systems:

[0100]

[0101] The comparative experimental results can guide the method of the present invention to use 10 μl-20 μl, most preferably 10 μl, of culture fluid volume for the post-resuscitation culture system.

[0102] Example 5. Research results

[0103] Baseline data of subjects

[0104] 212 frozen blastocysts were thawed based on morphology. According to routine embryo laboratory procedures, the blastocysts were transferred to transfer dishes after 6 hours of single droplet culture for single blastocyst transfer under ultrasound guidance, and the clinical outcomes of the pregnant women were followed up. The embryo droplet culture medium was collected simultaneously for NICS testing. SCM was not collected from 2 embryos, so 210 pregnant women were finally included. The NICS test results were: 53 cases of SCM amplification failure, amplification failure resulting in insufficient sequencing data for analysis, or sequencing data of the amplified products did not meet the analysis standards, 89 cases were euploid, and 68 cases were aneuploid (see Figure 1 ).

[0105] Table 5 shows the clinical baseline characteristics of all 210 pregnant women. According to the NICS results of the embryos, the pregnant women were divided into euploid, aneuploid and NA groups. The included baseline characteristics are: age, BMI, years of infertility, fertilization type, infertility type, cause of infertility, days of blastocyst, and blastocyst morphology rating of both men and women. Among them, the morphological rating is based on the classification criteria in Munne's article, and the embryos are divided into excellent, medium and poor. Excellent: AA / BA / AB; medium: BB / AC; poor: CA / BC / CB. Most of the indicators were not statistically significant in the three groups. Only the age of men and women, fertilization method, primary or secondary infertility, embryo days and morphological rating were significantly different. (Table 5)

[0106] Table 5 Clinical baseline characteristics of pregnant women

[0107]

[0108] Chromosome Screening Results and Clinical Outcomes

[0109] A total of 210 pregnant women were included, including 1 ectopic pregnancy and 1 late miscarriage. The clinical pregnancy rate was 48.6% (102 / 210), the ongoing pregnancy rate was 39.5% (83 / 210), the early miscarriage rate was 17.6% (18 / 102), and the live birth rate was 39.0% (82 / 210) ( Figure 1 ).

[0110] The age of both sexes, morphological rating, embryonic days, fertilization method and infertility type were included as independent variables in binary logistic regression analysis. The results showed that the clinical pregnancy rate, ongoing pregnancy rate and live birth rate in the euploid group were higher than those in the aneuploid group (56.2% vs 29.4%, adjusted OR 0.33, 95% CI 0.15-0.72; 47.2% vs 22.1%, adjusted OR 0.34, 95% CI 0.15-0.77; 46.1% vs 22.1%, adjusted OR 0.39, 95% CI 0.18-0.86), and there was statistical significance (see Table 6).

[0111] There was no significant difference in the clinical pregnancy rate, miscarriage rate, ongoing pregnancy rate and live birth rate between the euploid group and the NA group (56.2% vs 60.4%, adjusted OR 0.85, 95% CI 0.39-1.85; 47.2% vs 49.1%, adjusted OR 0.76, 95% CI 0.36-1.63; 46.1% vs 49.1%, adjusted OR 0.78, 95% CI 0.37-1.67) (see Table 6), that is, the two groups had similar outcomes.

[0112] Table 6 Logistic regression analysis to compare clinical outcomes among euploid, aneuploid and NA groups

[0113]

[0114] a Logistic regression analysis was adjusted for partner age, morphological grade, embryonic day, fertilization method, and primary or secondary infertility. * represents p<0.05, ** Represents p<0.01.

[0115] According to the morphological rating, the embryos were divided into three groups: excellent, medium and poor. The proportion of euploids in different ratings was 41.8%, 42% and 44.0%, which was basically the same. The proportion of aneuploids was 21.5%, 34.6% and 46.0%, which showed that the proportion of aneuploids increased with the worse rating. The overall clinical pregnancy rate, continuous pregnancy rate and live birth rate increased with the improvement of embryo rating (59.5% vs 44.4% vs 38.0%, p = 0.038; 49.4% vs 39.5% vs 24.0%, p = 0.016; 49.4% vs 39.5% vs 22.0%, p = 0.008). The abortion rate of embryos rated as "poor" was higher than that of the other two groups (17.0% vs 11.1% vs 31.6%), but no significant difference was found (p = 0.172). Only in the population with embryo rating of medium, the clinical pregnancy rate of the three groups was significantly different (p = 0.037), and the euploid group was higher than the aneuploid group (p = 0.014). It was also found that the NA group had the highest proportion of high-quality embryos (54.7%, 29 / 53, see Table 7). This stratified analysis also showed that although the morphological evaluation results of the embryos are very important factors, they are not enough to be used alone to predict the outcome of frozen embryos.

[0116] Table 7 Comparison of clinical outcomes according to embryo morphology grade

[0117]

[0118] As described above, in this study, the inventors retrospectively analyzed the NICS test results of the culture medium of 210 frozen blastocysts thawed and the clinical outcomes of pregnant women who underwent single blastocyst transfer according to morphologically selected embryos.

[0119] The clinical pregnancy rate, ongoing pregnancy rate, and live birth rate in the euploid group were significantly higher than those in the aneuploid group (56.2% vs 29.4%, adjusted OR 0.33, 95% CI 0.15-0.72; 47.2% vs 22.1%, adjusted OR 0.34, 95% CI 0.15-0.77; 46.1% vs 22.1%, adjusted OR 0.39, 95% CI 0.18-0.86), but not significantly different from those in the NA group (56.2% vs 60.4%, adjusted OR 0.85, 95% CI 0.39-1.85; 47.2% vs 49.1%, adjusted OR 0.76, 95% CI 0.36-1.63; 46.1% vs 49.1%, adjusted OR 0.78, 95% CI 0.37-1.67). If the pregnant woman transplants euploid embryos, the clinical outcome will be improved compared with aneuploid embryos, which is consistent with previous studies. There were also live births in the aneuploid group (22.1%), indicating that there are certain false positives in the test results or that the embryos have the ability to repair themselves. However, as a guideline, the test results of aneuploidy indicate that the transplantation of such embryos will be accompanied by great risks and the expectation of success is relatively low. Therefore, it is necessary for the pregnant woman and the doctor to discuss and decide whether to transplant based on comprehensive factors after being fully informed of the risks.

[0120] It can be concluded from Tables 6 and 7 that the clinical pregnancy rate, ongoing pregnancy rate and live birth rate between the NA group and the euploid group were not much different (56.2% vs 60.4%, adjusted OR 0.85, 95% CI 0.39-1.85; 47.2% vs 49.1%, adjusted OR 0.76, 95% CI 0.36-1.63; 46.1% vs 49.1%, adjusted OR 0.78, 95% CI0.37-1.67). It is speculated that the proportion of "good" embryos in this group was high (54.7% vs 37.1% vs 25.0%), and the embryonic cells were relatively dense, resulting in less DNA released into the culture medium, thus producing an "NA" result. Magli et al. also found in their study that after successful blastocyst fluid expansion embryo transfer, only 37% of the expectant mothers achieved clinical pregnancy and 18% achieved ongoing pregnancy; while after failed blastocyst fluid expansion embryo transfer, the clinical pregnancy rate was 77% and the ongoing pregnancy rate was 70%. Therefore, when there are no euploid embryos, after fully explaining the risks to the expectant mother and obtaining her full informed consent, it is possible to consider transplanting embryos with a high morphological grade but NA.

[0121] Therefore, among euploid embryos, embryos with excellent morphology should be transplanted first. Based on the results of live birth rate, we recommend the following order of embryo priority transplantation: euploid + excellent → NA + excellent → euploid + intermediate → NA + intermediate (see Table 7 and Figure 2 ).

[0122] All publications, patents and patent applications mentioned throughout the specification, including the references listed below, are hereby incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application were expressly and individually stated to be incorporated by reference in its entirety. Various modifications and variations of the products, methods, or uses of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in conjunction with specific embodiments, it should be understood that it is capable of further modification, and the claimed invention should not be unduly limited to such specific embodiments. In fact, it will be apparent to those skilled in the art that various modifications of the modes for implementing the present invention are intended to be within the scope of the present invention. This application is intended to cover any variation, use or adaptation of the present invention, which generally follows the principles of the present invention, and includes such deviations from the present disclosure that are within the known practices in the field to which the present invention belongs, and can be applied to the basic features shown above.

[0123] References:

[0124] 1. Kupka MS, et al. (2014) Assisted reproductive technology in Europe, 2010: results generated from European registers by Human reproduction(Oxford,England)29(10)p:2099-2113.

[0125] 2. Maheshwari A, Griffiths S, & Bhattacharya S (2011) Global variations in the uptake of single embryo transfer. Human reproduction update 17(1)p:107-120.

[0126] 3.Minasi MG,et al.(2016)Correlation between aneuploidy,standardmorphology evaluation and morphokinetic development in 1730 biopsiedblastocysts:a consecutive case series study.Human reproduction(Oxford,England)31(10)p:2245-2254.

[0127] 4.Alfarawati S,et al.(2011)The relationship between blastocystmorphology,chromosomal abnormality,and embryo gender.Fertility and sterility95(2)p:520-524.

[0128] 5.Scott RT,et al.(2012)Comprehensive chromosome screening is highlypredictive of the reproductive potential of human embryos:a prospective,blinded,nonselection study.Fertility and sterility 97(4)p:870-875.

[0129] 6.Sahoo T,et al.(2017)Comprehensive genetic analysis of pregnancyloss by chromosomal microarrays:outcomes,benefits,and challenges.Genetics inmedicine:official journal of the American College of Medical Genetics 19(1)p:83-89.

[0130] 7.Chen M,Wei S,Hu J,&Quan S(2015)Can Comprehensive ChromosomeScreening Technology Improve IVF / ICSI Outcomes?A Meta-Analysis.PloS one 10(10)p:e0140779.

[0131] 8.Rubio C,et al.(2017)In vitro fertilization with preimplantationgenetic diagnosis for aneuploidies in advanced maternal age:a randomized,controlled study.Fertility and sterility 107(5)p:1122-1129.

[0132] 9.Zhang S,et al.(2016)Number of biopsied trophectoderm cells islikely to affect the implantation potential of blastocysts with poortrophectoderm quality.Fertility and sterility 105(5)p:1222-1227.e1224.

[0133] 10.Guzman L,et al.(2019)The number of biopsied trophectoderm cellsmay affect pregnancy outcomes.Journal of assisted reproduction and genetics36(1)p:145-151.

[0134] 11.Middelburg KJ,et al.(2010)Neurological condition of infants bornafter in vitro fertilization with preimplantation genetic screening.Pediatricresearch 67(4)p:430-434.

[0135] 12.Middelburg KJ,et al.(2011)Mental,psychomotor,neurologic,andbehavioral outcomes of 2-year-old children born after preimplantation geneticscreening:follow-up of a randomized controlled trial.Fertility and sterility96(1)p:165-169.

[0136] 13.Tobler KJ,et al.(2015)Blastocoel fluid from differentiatedblastocysts harbors embryonic genomic material capable of a whole-genomedeoxyribonucleic acid amplification and comprehensive chromosome microarrayanalysis.Fertility and sterility 104(2)p:418-425.

[0137] 14.Hammond ER,Shelling AN,&Cree LM(2016)Nuclear and mitochondrial DNAin blastocoele fluid and embryo culture medium:evidence and potentialclinical use.Human reproduction(Oxford,England)31(8)p:1653-1661.

[0138] 15.Farra C,Choucair F,&Awwad J(2018)Non-invasive pre-implantationgenetic testing of human embryos:an emerging concept.Human reproduction(Oxford,England)33(12)p:2162-2167.

[0139] 16.Stigliani S,Anserini P,Venturini PL,&Scaruffi P(2013)MitochondrialDNA content in embryo culture medium is significantly associated with humanembryo fragmentation.Human reproduction(Oxford,England)28(10)p:2652-2660.

[0140] 17.Kuznyetsov V,et al.(2018)Evaluation of a novel non-invasivepreimplantation genetic screening approach.PloS one 13(5)p:e0197262.

[0141] 18.Huang L,et al.(2019)Noninvasive preimplantation genetic testingfor aneuploidy in spent medium may be more reliable than trophectodermbiopsy.Proceedings of the National Academy of Sciences of the United Statesof America 116(28)p:14105-14112.

[0142] 19.Jiao J,et al.(2019)Minimally invasive preimplantation genetictesting using blastocyst culture medium.Human reproduction(Oxford,England)34(7)p:1369-1379.

[0143] 20.Li X,et al.(2021)Non-invasive preimplantation genetic testing forputative mosaic blastocysts:a pilot study.Human reproduction(Oxford,England)36(7)p:2020-2034.

[0144] 21.Sciorio R,Thong KJ,&Pickering SJ(2019)Increased pregnancy outcomeafter day 5 versus day 6 transfers of human vitrified-warmedblastocysts.Zygote(Cambridge,England)27(5)p:279-284.

[0145] 22.Du QY,et al.(2016)Blastocoele expansion degree predicts live birthafter single blastocyst transfer for fresh and vitrified / warmed singleblastocyst transfer cycles.Fertility and sterility 105(4)p:910-919.e911.

[0146] 23.Gao FF,et al.(2021)ChromInst:A single cell sequencing technique toaccomplish pre-implantation comprehensive chromosomal screeningovernight.PloS one 16(5)p:e0251971.

[0147] 24.Gardner DK,Lane M,Stevens J,Schlenker T,&Schoolcraft WB(2000)Blastocyst score affects implantation and pregnancy outcome:towards a singleblastocyst transfer.Fertility and sterility 73(6)p:1155-1158.

[0148] 25.Chen L,et al.(2021)A Non-invasive Chromosome Screening Strategyfor Prioritizing in vitro Fertilization Embryos for Implantation.Front CellDev Biol 9p:708322.

[0149] 26.Rubio C,et al.(2020)Multicenter prospective study of concordancebetween embryonic cell-free DNA and trophectoderm biopsies from 1301humanblastocysts.American journal of obstetrics and gynecology 223(5)p:751.e751-751.e713.

[0150] 27.MunnéS,et al.(2019)Preimplantation genetic testing for aneuploidyversus morphology as selection criteria for single frozen-thawed embryotransfer in good-prognosis patients:a multicenter randomized clinicaltrial.Fertility and sterility 112(6)p:1071-1079.e1077.

[0151] 28.Dang TT,et al.(2019)Preimplantation Genetic Testing of Aneuploidyby Next Generation Sequencing:Association of Maternal Age and ChromosomalAbnormalities of Blastocyst.Open access Macedonian journal of medicalsciences 7(24)p:4427-4431.

[0152] 29.Sainte-Rose R,Petit C,Dijols L,Frapsauce C,&Guerif F(2021)Extendedembryo culture is effective for patients of an advanced maternalage.Scientific reports 11(1)p:13499.

[0153] 30.Magli MC,et al.(2019)Deoxyribonucleic acid detection inblastocoelic fluid:a new predictor of embryo ploidy and viablepregnancy.Fertility and sterility 111(1)p:77-85.

[0154] 31.Chen L,et al.(2021)The effects of the day of trophectoderm biopsyand blastocyst grade on the clinical and neonatal outcomes of preimplantationgenetic testing-frozen embryo transfer cycles.Zygote(Cambridge,England)p:1-6.

[0155] 32. Kovalevsky G, et al. (2013) Should embryos developing to blastocystson day 7be cryopreserved and transferred: an analysis of pregnancy and implantation rates. Fertility and sterility 100(4)p:1008-1012.

[0156] 33.Peng X, et al. (2020) Effects of euploid blastocyst morphologicaldevelopment on reproductive outcomes. Reproductive biology 20(4)p:496-500.

[0157] 34. Lynch C, et al. (2019) 16. Intracytoplasmic Sperm Injection Is NotNecessary as a Preventive Measure against Paternal Cell Contamination in Preimplantation Genetic Testing. Reproductive biomedicine online 39p:e24-e25.

[0158] 35. De Munck N, et al. (2020) Intracytoplasmic sperm injection is not superior to conventional IVF in couples with non-male factor infertility and preimplantation genetic testing for aneuploidies (PGT-A). Human reproduction (Oxford, England) 35 (2) p: 317-327.

[0159] 36. Liu Yanli, Shen Junhan, Zhang Yuchao, et al. Effect of embryo cryopreservation time on clinical outcomes and neonatal outcomes of cryopreservation cycles[J]. Journal of Zhengzhou University: Medical Edition, 2021, 56(6):7.

[0160] 37. Cui Tingting, Ji Changli, Yang Yang, et al. Application of laser-assisted hatching technology in frozen-thawed blastocyst transfer[J]. Shandong Medicine, 2022, 62(7):4.

[0161] 38.Sciorio R,Thong KJ,Pickering S J.Increased pregnancy outcomeafter day 5versus day 6transfers of human vitrified-warmed blastocysts[J].Zygote,2019,27(5):1-6.

[0162] 39. Ye Xiaoqing, Gao Ya, Song Xiwei, et al. Evaluation of the detection efficiency of non-invasive prenatal genetic testing technology based on low-depth sequencing for fetal chromosome copy number variation[J]. Journal of Practical Obstetrics and Gynecology, 2020, 36(5):5.

Claims

1. A method for assessing the priority of frozen embryo transfer for non-diagnostic / therapeutic purposes, comprising the following steps: (1) Obtaining frozen embryos from prospective pregnant women; (2) thawing the frozen embryos and transferring them into a microdroplet culture system for culture, wherein the culture time is T1; (3) Collecting the culture medium, amplifying the cfDNA therein, and then conducting embryonic chromosome genetic testing; (4) Prioritize embryo transfer based on the results of chromosome genetic testing and morphological assessment prior to embryo freezing; The results of chromosome genetic testing are divided into three types: euploid, NA and aneuploid; the results of morphological evaluation are divided into three types: excellent, fair and poor; the priority of embryo transplantation is evaluated according to the above results as follows: euploid + excellent > NA + excellent > euploid + fair > NA + fair. For embryos with aneuploid chromosome genetic testing and / or poor morphological evaluation, the clinician and the patient will jointly decide whether to transplant them if the patient is fully informed of the risks. Among them, the meaning of "euploid" in the chromosome genetic test result is: when the mosaicism degree of free DNA from the embryo in the sample is lower than 30%, the chromosome of the embryo is considered to be euploid; the meaning of "aneuploid" in the chromosome genetic test result is: when the mosaicism degree of free DNA from the embryo in the sample is higher than 70%, the chromosome of the embryo is considered to be aneuploid; the meaning of "NA" in the chromosome genetic test result is: amplification failure occurs, amplification failure leads to insufficient sequencing data for analysis, and / or the sequencing data of the amplified product does not meet the analysis standard, so the ploidy test result of the embryo is not obtained, and it is classified as "NA".

2. The method according to claim 1, wherein the volume of the microdroplet culture system is 10 μL-20 μL.

3. The method of claim 1, wherein the culture time T1 is 4-10 hours.

4. The method of claim 1, wherein the culture time T1 is 6-8 hours.

5. A system for frozen embryo transplantation, comprising the following modules: 1) Embryo recovery and culture module: the module is used to recover and culture frozen embryos obtained from pregnant women; 2) Embryo detection module: This module is used to collect the embryo culture medium in module 1), amplify the cfDNA therein, perform embryo chromosome genetic testing, and obtain the results of morphological evaluation before embryo freezing; 3) Result analysis module: Based on the embryo chromosome genetic test results and morphological evaluation results output by module 2), analyze the priority level of the corresponding embryo for transplantation. Chromosome genetic testing is divided into three results: euploid, NA and aneuploid; morphological evaluation is divided into three results: excellent, medium and poor; the priority of embryo transplantation is assessed according to the above results: euploid + excellent > NA + excellent > euploid + medium > NA + medium. For embryos with aneuploidy in genetic testing and / or poor morphological evaluation, the clinician and the patient will jointly decide whether to transplant them if the patient is fully informed of the risks. in, The meaning of "euploid" in the chromosome genetic test result is: when the mosaicism degree of free DNA from the embryo in the sample is lower than 30%, the chromosome of the embryo is considered to be euploid; the meaning of "aneuploid" in the chromosome genetic test result is: when the mosaicism degree of free DNA from the embryo in the sample is higher than 70%, the chromosome of the embryo is considered to be aneuploid; the meaning of "NA" in the chromosome genetic test result is: amplification failure occurs, amplification failure leads to insufficient sequencing data for analysis, and / or the sequencing data of the amplified product does not meet the analysis standard, so the ploidy test result of the embryo is not obtained, and it is classified as "NA". 6 . The system according to claim 5 , wherein the embryo recovery culture module adopts a droplet culture system with a culture volume of 10 μL-20 μL.

7. The system as claimed in claim 5, wherein the embryo recovery culture module adopts a culture time of 4-10 hours.

8. The system as claimed in claim 5, wherein the embryo recovery culture module adopts a culture time of 6-8 hours.

9. The system as claimed in claim 5, wherein the embryo recovery culture module adopts a culture time of 6 hours.

Citation Information

Patent Citations

  • Method for detecting embryo health by using blastocyst culture solution, and product

    CN109536581A

  • System and method for non-invasive embryo transplantation priority rating

    CN112582022A

  • Method and product for detecting embryo health condition by using blastocyst culture solution

    CN113286892A